We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Which is exactly what Angle Plc are working on with Bioview:-
Astrazeneca RNS of 8th April:-
"Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
for previously treated patients with metastatic HER2-positive solid tumours"
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
Astrazeneca RNS of 2nd April:-
"Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer"
https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html
Petro - assuming this is on the wrong page from you? 😂. Currently flat after a massive 10% increase yesterday, down by 50% on the 3 month chart 😂🤷♂️
Looking at your posts, can only suspect you’ve been spiked at some point in the past. Maybe better to learn from it and move on rather than spend your whole days as a white knight for others - we’re all able to make decisions on our own (not necessarily the right ones every time of course).
Just make sure to sell before the pumpers dump. Beware of people who give you stock tips with random price targets. They are likely pump-and-dumpers who are trying to offload their shares at a higher price. Newbies often fall for this scam and end up losing money.
Moab
" I see no reason why Parsortix could not be used to help detect the HER-2 levels in all cancer types."
Reason: I think you will find that HER status applies only to breast cancer.".
============================================
Incorrect. The Astrazeneca RNS just yesterday (see link below) names many cancers as you can see:-
"HER2-directed therapies have been used to treat breast, gastric, lung and colorectal cancers for a number of years.3,6,7 Although HER2 is expressed in solid tumour types including biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers, testing is not routinely performed in these additional tumour types and as a result, available literature is limited.4 In these solid tumours, HER2-positive expression, classified as immunohistochemistry (IHC) 3+, has been observed at rates from 1% to 28%.8,9 Approximately 1% to 5% of patients with NSCLC have tumours with HER2 overexpression (IHC 3+), however, the levels of protein expression reported vary in the literature.8,10 Approximately 1% to 4% of patients with metastatic colorectal cancer have tumours which are HER2 overexpressing (IHC 3+).8,11,12
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
All IMHO.
New York, February 10, 2022.
Note these are just the trials that include a PD1/PDL1-targeting agent.....................
"The number of clinical trials started each year that include a PD1/PDL1-targeting agent has continued to increase, currently at 5,683 worldwide, up 278% from the number of trials reported in 2017.".
https://www.cancerresearch.org/media-room/2022/pd1-pdl1-clinical-trials-combo-mono
Carrot
" I see no reason why Parsortix could not be used to help detect the HER-2 levels in all cancer types."
Reason: I think you will find that HER status applies only to breast cancer.
Moab
You should take a day off as working on this thread and Advfn 7 days a week is affecting your mental health
"Breast cancer is the most common cancer worldwide. There were more than 2.26 million new cases of breast cancer in women in 2020."
https://www.wcrf.org/cancer-trends/breast-cancer-statistics/
FACT!
Hopester.
"Would I be right in thinking that since Enhertu is tumour agnostic and the only information required for successful treatment is the tumour HER2 status, that Parsortix could be applied to CTC detection in all cancer types?".
===========================
The Parsortix machine can catch circulating tumour cells (CTC's) of all cancer types as I understand it. In fact the blood sample can even be from other animals. Then for **cancer drug trials** the captured cells can be tested for their HER-2 status. However Parsortix, thus far, is only approved in the USA for catching ***Breast Cancer*** CTC's for analysis at what you might call cancer clinic level. For the other cancer types it can only be used in the USA during cancer drug trials. Having said that there is a huge World market for Breast Cancer treatment and a huge World wide market for drug trials. The numbers are staggering. So in time, after more FDA approvals are sought for other types of cancer and hopefuly got, I see no reason why Parsortix could not be used to help detect the HER-2 levels in all cancer types.
The Bioview part introduces automation and A.I to quickly detect the HER-2 status of a captured circulating tumour cell (CTC).
All IMHO.
Would I be right in thinking that since Enhertu is tumour agnostic and the only information required for successful treatment is the tumour HER2 status, that Parsortix could be applied to CTC detection in all cancer types?
All buys btw it was 13.2p to buy then 13.45p then 13.7p to buy right at the close. Might go on a run now it's held it's gains for the first time in months
Up 10.2% now!
is significant as I said.
The sp has moved up steadily all day.
School finishes. Would have us believe she holds some. What a joke that is.
Up 8.16% USA money?
The bottom line is these Companies who now have drugs that can home in on HER-2 positive cancers desperately need a way to find out what the HER-2 status of a persons cancer is before, during and after treatment. Angle Plc are working on just that.
All IMHO.
Nice to see it go up and up intraday for a change, normally one sell and they all sell. Maybe this time it can go on a little run
Amen to that
EC.
Can you stop ramping and clutching at straws ffs!
Astra Zenenica are developing their own alternatives.
Astrazeneca have got FDA approval (so they can be used in the USA) for a treatment that targets cancers that are HER2-positive (IHC 3+). From the Astrazeneca RNS:-
"AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.".
From Angle's announcement also this morning:-
"The combination of ANGLE's Parsortix system for harvesting CTCs for analysis, BioView's imaging and analysis technologies, and the new HER2 CTC staining kit under development is intended to provide an easy to use assay based on a simple blood test, providing an up-to-date HER2 status for breast cancer patients on a repeat basis.".
So AstraZeneca, and indeed any Company in the World who's cancer drug targets HER-2 need to know the patients HER-2 status to see if that are suitable and monitor it over time as treatment is given. Angle's contract with Eisai announced by Angle on 2nd Jan is also relevant. See links below.
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html
All IMHO.
To Agl?". It seems to me better ways of testing the HER2 status of cancers are desperateky needed so the people these drugs might benefit can be identified. Angle's announcement this morning shows they are making good progress in this area. Hopefully the likes of Astrazeneca are keeping an eye.......
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
PM01 / oilhead
I don't understand your comments. Ehertu is a drug, AGL's Parsortix is a diagnostic procedure.
Yes I saw that. I also note 'This approval was granted under the FDA's Real-Time Oncology Review programme after securing Priority Review and Breakthrough Therapy Designation for Enhertu in the US in this setting. The US regulatory submission was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, Enhertu is also under regulatory review for the same indication by regulatory authorities in Australia, Brazil and Singapore.' Somewhat different approach than AGL's.
Did you see AstraZeneca news today regarding her2 is it similar to Agl?
AGL are very good at being Poster Boys( and Girls)
https://www.londonstockexchange.com/news-article/AGL/parsortix-her2-assay-showcased-at-aacr-2024/16411145
When will they transition to the next stage in the companies development and what dynamics are at play in the global pharmaceuticals industry preventing its commercial uptake, or is the device being overtaken by other, more suitable, tools and techniques?
I've been invested here for many years in and out at various times and still invested and still scratching my head on what action to take. It's sometimes a head and a heart discussion!